Danaher: Cytiva & the Chromatography Process
Former Head of Sales, GE Life Sciences
inpractise.com/articles/danaher-cytiva-pharmacia-and-the-chromatography-process
Danaher: Cytiva & the Chromatography Process(July 24, 2024)
Former Head of Sales, GE Life Sciences
Interview Transcript
This is a snippet of the transcript.Contact Salesto get full access.
What would you be worried about if you were running Cytiva over next 10 years?
I would be worried about future developments within genetic engineering. I'm sure there will be some minor effects. The problem is that, you know, GE Amersham, or whatever we call it, we worked with that. We have the technology to produce genetic material on a large scale, but there are very few successes.
This is a snippet of the transcript.Contact Salesto get full access.
Related Content
Danaher, Cytiva: Downstream Sales Process
Former Head of Sales, GE Life Sciences
Danaher & the Bioprocessing FDA Approval Process
Former Head of Sales, GE Life Sciences
Danaher: Cytiva, HyClone, & Cell Culture Sales
Former Sales Specialist at Cytiva
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.